The blockade of the RAS with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor (AT1R) antagonists has been shown to reduce proteinuria and retard DN progression (6). The gene discussed is AGTR1; the disease is liver dysplastic nodule.